Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1209 in advanced solid tumors
NCT06872580Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of QLS1209 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (TRAEs), Serious Adverse Events (SAEs) up to 2 years, Maximum Tolerated Dose (MTD) / Maximum Administered Dose (MAD) and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
QLS1209
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06872580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872580.